Mitochondrial-derived peptide ('exercise mimetic')
A 16-amino-acid peptide encoded in mitochondrial DNA that acts as a metabolic signaling molecule.
| Class / type | Mitochondrial-derived peptide ('exercise mimetic') |
|---|---|
| Category | Longevity & Cellular |
| Status (Jul 2026) | Research use only |
MOTS-c is a small peptide encoded within mitochondrial DNA that acts as a metabolic signaling molecule. Interest centers on its role as a natural 'exercise signal' - blood levels rise with physical activity - and on animal data suggesting it improves metabolism.
Human clinical trials are essentially absent, so its marketing (energy, fat loss, endurance) runs well ahead of the proof. It is sold research-use-only.
MOTS-c activates AMPK, the enzyme that governs cellular energy balance, largely through the folate-AICAR pathway. This increases muscle glucose uptake and fat oxidation, and under metabolic stress MOTS-c can move into the nucleus to influence gene expression.
Preclinical (cell and rodent) studies show improved insulin sensitivity, endurance and glucose handling, and human observational work shows circulating MOTS-c rises with exercise. But direct human efficacy trials are lacking, so benefits in people are extrapolated rather than demonstrated.
A compelling 'exercise-in-a-vial' rationale, with preclinical support for metabolic and endurance effects.
Users report increased energy and exercise capacity, though this is anecdotal.
Human safety data are minimal because clinical trials are essentially absent. Injection-site reactions are possible, and gray-market purity is a concern.
The gap between marketing claims and actual human evidence is large - a key thing for readers to weigh.
Sold research-use-only. It is also under 2026 FDA compounding review (with the FDA proposing not to list it). No FDA-sanctioned human dose exists.
'Exercise in a vial' - perceived energy, endurance and fat-loss support with training.
NOT FDA-approved; research-use-only. Removed from Category 2 (Apr 2026); under PCAC review Jul 23, 2026 (FDA proposing NOT to list). Verify.